Daptomycin Lyophilized Powder Reconstitution Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current daptomycin formulations for parenteral administration have slow reconstitution times and limited chemical stability, which affects their efficacy and shelf life, especially under varying storage conditions.
Innovation Solution
The development of solid daptomycin compositions that are lyophilized from an aqueous solution with a pH adjusted to 6.5-7.5, often incorporating non-reducing sugars like sucrose or glycine, to enhance reconstitution speed and chemical stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If daptomycin is formulated in conventional lyophilized form, then chemical stability is maintained, but reconstitution time is slow
Solution Approach 1:
The patent adjusts the pH of the aqueous solution to a specific range (pH 6.5-7.5) before lyophilization, which fundamentally changes the chemical environment and physical properties of the daptomycin formulation. This parameter change enables the formation of a lyophilized cake structure that reconstitutes rapidly while maintaining chemical stability, directly resolving the contradiction between reconstitution speed and stability.
2Speed
If pH is adjusted to 6.5-7.5 before lyophilization, then reconstitution speed increases, but chemical stability may be compromised
Solution Approach 1:
The patent carefully controls the pH parameter within a specific range (6.5-7.5) that optimizes both reconstitution speed and chemical stability. This precise parameter control allows the formulation to achieve rapid reconstitution while preventing degradation, resolving the contradiction between speed and stability.
Solution Approach 2:
The patent incorporates excipients that act as intermediaries to protect daptomycin from degradation at the optimized pH level. These excipients stabilize the molecule during storage and prevent hydrolysis or other degradation pathways, enabling both fast reconstitution and maintained chemical stability.
3Ease of manufacture
If conventional lyophilization is used without pH optimization, then manufacturing is simpler, but reconstitution time increases
Solution Approach 1:
The patent introduces pH adjustment as a controlled parameter in the lyophilization process. While this adds a step to the manufacturing process, it significantly reduces reconstitution time from hours to minutes. The benefit of rapid reconstitution outweighs the moderate increase in manufacturing complexity, resolving the contradiction between ease of manufacture and reconstitution time.
4Adaptability or versatility
If storage conditions are varied, then adaptability increases, but chemical stability decreases
Solution Approach 1:
The optimized pH formulation (pH 6.5-7.5) creates a more robust chemical environment that is less sensitive to variations in storage conditions. This parameter optimization provides a buffer against pH shifts that might occur during storage, allowing greater flexibility in storage conditions while maintaining chemical stability.
Solution Approach 2:
The formulation includes excipients and pH buffers that provide protective cushioning against environmental stresses before they can cause degradation. This preemptive protection allows the formulation to withstand varied storage conditions without compromising daptomycin stability, resolving the contradiction between adaptability and stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compositions reconstitute rapidly in aqueous diluents within minutes and exhibit significantly improved chemical stability, maintaining high daptomycin purity over time, even under stressful storage conditions.
Implementation Method 1
The present invention relates to solid lipopeptide compositions for reconstitution in aqueous diluent to form pharmaceutical compositions. The lipopeptide compositions are prepared by converting a pharmaceutically acceptable aqueous solution including the lipopeptide into the solid lipopeptide composition (e.g., by lyophilization, spray drying or the like).
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present disclosure provides novel powder daptomycin formulations which have improved chemical stability and faster reconstitution times when in the solid state. Some examples of the compositions comprise daptomycin and sucrose.